CAR T Cells in Cancer Gene Therapy
- Nov 4, 2024
- 3:00PM TO 4:00 PM
- 00Days
- 00Hours
- 00Minutes
- 00Seconds
About the Case Presentation
CAR T-cell therapy is a groundbreaking approach in cancer gene therapy that harnesses a patient’s immune cells to target and destroy cancer cells. In this technique, T-cells are genetically modified to express chimeric antigen receptors (CARs) that specifically recognize cancer cells. Once reintroduced into the patient, these CAR T-cells seek out and eliminate cancer cells with high precision. This therapy has shown remarkable success in treating certain types of blood cancers, such as leukemia and lymphoma, and is being explored for solid tumors. CAR T-cell therapy offers a promising personalized treatment, with ongoing research aimed at enhancing its safety, effectiveness, and applicability to a wider range of cancers.
About the Speaker
Dr. Shibichakravarthy Kannan
Consultant Medical Genetics, Apollo Health and Lifestyle Limited, Hyderabad
Dr. Shibichakravarthy Kannan, MBBS, PhD is a Founder & CEO at Theranosis Life Sciences Pvt Ltd. He is a Physician Scientist from Chennai, India – trained in the USA . He has 15 years of clinical & translational research experience including 3 years of Industry experience in the areas – Bioinformatics, Next Generation Sequencing, Scientific communications at Novartis, Drug Discovery & Development, Clinical Genetics & tumor immunotherapy. Dr Kannan’s research focuses on Tumor Immunology & Immunotherapy. He has more than 20 research publications in high impact peer reviewed medical journals. He is Biobanking Expertise – Founded the Lymphoma Tissue Biobank at MD Anderson; replicating this model in Hyderabad & Bangalore, India and Circulating Tumor Cells – developing a platform for performing liquid biopsy of most common solid tumors such as breast, lung, prostate and colorectal cancer.